<DOC>
	<DOCNO>NCT00073008</DOCNO>
	<brief_summary>This study design evaluate compare efficacy two dose schedule oral investigational drug treatment advance metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Signed informed consent ; Subjects must histologically confirm advanced ( incurable stage IIIB IV accord International Staging System , [ Mountain , 1997 ] NonSmall Cell Lung Cancer ( NSCLC ) primary diagnosis relapse curativeintent surgery . Only patient either ( 1 ) histological subtypes adenocarcinoma BAC ( Bronchioloalveolar ) feature pure BAC ( define 1999 World Health Organization criterion ) , ( 2 ) never smoker ( i.e . smoke &lt; 100 cigarette lifetime ) histology NSCLC ( squamous , adenocarcinoma , lifetime ) histology NSCLC ( squamous , adenocarcinoma , Patients maximum 1 prior systemic therapy ( chemotherapy biologic therapy ) NSCLC end least 3 week prior enrollment . Patients adjuvant cytotoxic chemotherapy end least 3 month prior enrollment eligible . Prior surgery radiotherapy permit . Patients recover acute side effect radiation enrollment ( 34 week ) . Concurrent radiotherapy prohibit ; Archived tumor tissue available evaluation genetic intratumoral protein mRNA expression level relevant biomarkers . A minimum 10 slide archive tumor tissue require ; however , 15 slide send , available . For patient diagnosed basis pleural effusion , effort make provide many slide possible make cell obtained pleural aspirate . Results biomarkers use determine subject eligibility study ; Measurable lesion ( ) accord RECIST ( e.g. , ≥15 mm conventional technique ( medical photograph [ skin oral lesion ] , palpation , plain Xray , CT , MRI , ≥10 mm spiral CT scan ) ; At least 1 measurable lesion locate outside prior radiation field , locate within prior field irradiation , increase size ; Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 ; Life expectancy ≥ 12 week ; ≥ 18 year old ; A female eligible enter participate study : • Nonchildbearing potential ( i.e. , woman function ovary current document tubal ligation , woman hysterectomy , woman postmenopausal , woman ovary surgically remove ) ; • Childbearing potential ( i.e. , woman function ovary document impairment oviductal uterine function would cause sterility ) . This category include woman oligomenorrhea ( even severe ) , woman perimenopausal , young woman begin menstruate . Women childbearing potential must negative serum pregnancy test screening , agree 1 follow : Complete abstinence intercourse 2 week prior administration first dose GW572016 28 day final dose GW572016 ; b Consistent correct use 1 follow acceptable method birth control : 1 . Male partner sterile prior female subject 's entry study sole sexual partner female subject ; 2 . Implants levonorgestrel 3 . Injectable progestogen 4 . Any intrauterine device ( IUD ) document failure rate le 1 % per year ; 5 . Oral contraceptive ( either combine Progestogen ) 6 . Barrier method include diaphragm condom spermicide Able swallow retain oral medication ; Cardiac ejection fraction within institutional range normal measure echocardiogram . Subjects know history uncontrolled symptomatic echocardiogram . Subjects know history uncontrolled symptomatic angina , arrhythmia , congestive heart failure eligible ; Have adequate organ function define Table 1 Baseline Laboratory Values Inclusion ; Subjects must complete screen assessment outline protocol . Malabsorption Syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel . Subjects ulcerative colitis also exclude ; History malignancy . Subjects diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible ; Concurrent disease condition would make subject inappropriate study participation , serious medical disorder would interfere subject 's safety ; Unresolved unstable , serious toxicity prior administration another investigational drug ; Active uncontrolled infection ; Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent ; Uncontrolled angina , arrhythmia , congestive heart failure . Patients whose symptom control eligible . Known history clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis except individual previously treat CNS metastasis , asymptomatic , requirement steroid antiseizure medication ≥ 3 month prior study enrollment . Routine screen CNS image study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) require clinically indicated subject history CNS metastases ; Concurrent cancer therapy ( chemotherapy , radiation therapy , surgery , immunotherapy , biologic therapy , hormonal therapy , tumor embolization ) . Concurrent treatment investigational agent participation another clinical trial Use investigational drug within 30 day 5 halflives , whichever longer , precede first dose GW572016 ; Prior therapy ErbB1 and/or ErbB2 inhibitor ; The subject know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate GW572016 . Has taken/received follow inhibitor CYP3A4 within specify number day prior first dose study medication : Seven ( 7 ) day : antibiotic ( clarithromycin , erythromycin , troleandomycin ) , antiretrovirals ( delavirdine ) , protease inhibitor ( ritonavir , indinavir , saquinavir , nelfinavir , amprenavir , lopinavir ) , systemic antifungal ( itraconazole , ketoconazole , voriconazole , fluconazole ( dose 200 mg/day ) ) , antidepressant ( nefazodone , fluovoxamine ) , calcium channel blocker ( verapamil , diltiazem ) , gastrointestinal ( cimetidine , aprepitant ) , grapefruit juice . Six ( 6 ) month : amiodarone . Has taken/received follow inducer CYP3A4 within fourteen ( 14 ) day prior first dose study medication : glucocorticoid ( dexamethasone dexamethasone equivalent dose &gt; 1.5mg/day ( see chart Section 7.2 conversion ) , anticonvulsant ( phenytoin , carbamazepine , phenobarbital ) , efavirenz , nevirapine , antibiotic ( rifampin ( rifampicin ) , rifabutin , rifapentine ) , St. John 's Wort modafinil .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>EGFR</keyword>
	<keyword>ErbB1</keyword>
	<keyword>ErbB2</keyword>
	<keyword>metastatic</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Her-2/neu</keyword>
	<keyword>protein kinase inhibitor</keyword>
	<keyword>BAC</keyword>
	<keyword>GW572016</keyword>
	<keyword>Advanced</keyword>
	<keyword>NSCLC</keyword>
</DOC>